Does TGF-β induced formation of actin stress fibres reinforce Smad dependent TGF-β signalling in the prostate?

Medical Hypotheses

Volumn 76, Issue 6, 2011, Pages 802-804

  Assinder, Stephen ^a   Cole, Nicholas ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; ACTIN BINDING PROTEIN; FILAMIN A; MITOGEN ACTIVATED PROTEIN KINASE; RAS PROTEIN; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSGELIN; TROPOMYOSIN;

ACTIN FILAMENT; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; HUMAN; HYPOTHESIS; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; STRESS FIBER;

ACTINS; HUMANS; MALE; PROSTATE; SIGNAL TRANSDUCTION; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA;

EID: 79955709156     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2011.02.021     Document Type: Article

References (33)

1. Masagué J. TGF-β signal transduction. Annu Rev Biochem 1998, 67:753-791.
2. Siegel P.M., Masagué J. Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer. Nat Rev Cancer 2003, 3:807-820.
3. Biswas S., Criswell T.L., Wang S.E., Arteaga C.L. Inhibition of transforming growth factor- β signalling in human cancer: targeting a tumor suppressor network as a therapeutic strategy. Clin Cancer Res 2006, 12:4142-4146.
4. Ueki N., Nakazato T., Ohkawa T., et al. Excessive production of transforming growth-factor β1 can play an important role in the development of tumorigenesis by its action for angiogenesis: validity of neutralising antibodies to block tumor growth. Biochem Biophys Acta 1992, 1137:189-196.
5. Pardali K., Moustakas A. Actions of TGF-β as a tumour suppressor and pro-metastatic factor in human cancer. Biochim Biophys Acta 2007, 1775:21-62.
6. Assinder SJ, Nicholson HD. In: Kandeel FR, editor. Male reproductive dysfunction: pathophysiology and treatment, New York: Informa Healthcare; 2007. p. 499-518 [chapter 41].
7. Hussain A., Dawson N. Management of advanced/metastatic prostate cancer: 2000 update. Oncology 2000, 14:1677-1688.
8. Reynolds A.R., Kyprianou N. Growth factor signalling in prostatic growth: significance in tumor development and therapeutic targeting. Brit J Pharmacol 2006, 147:S144-S152.
9. Gou Y., Kyprianou N. Restoration of transforming growth factor beta signalling pathway in human prostate cancer cells suppresses tumorigenicity via induction of caspase-1-mediated apoposis. Cancer Res 1999, 59:1366-1371.
10. Danielpour D. Functions and regulation of transforming growth factor-beta (TGF-β) in the prostate. Eur J Cancer 2005, 41:846-857.
11. Rahimi R.A., Leof E.B. TGF-β signalling: a tale of two responses. J Cell Biochem 2007, 102:593-608.
12. Ten Dijke P., Goumans M.J., Itoh F., Itoh S. Regulation of cell proliferation by Smad proteins. J Cell Physiol 2002, 191:1-16.
13. Masagué J., Blain S.W., Lo R.S. TGF β signaling in growth control, cancer, and heritable disorders. Cell 2000, 103:295-309.
14. Levy L., Hill C.S. Alterations in components of the TGF- superfamily signaling pathways in human cancer. Cytokine Growth Factor Rev 2006, 17:41-58.
15. Sasaki A., Masuda Y., Ohta Y., et al. Filamin associates with Smads and regulates transforming growth factor- β signaling. J Biol Chem 2001, 276:17871-17877.
16. Varga AE, Stourman NV, Zheng Q, et al. Silencing of the tropomyosin-1 gene by DNA methylation alters tumor suppressor function of TGF-β. Oncogene 2005;24:5043-5052.
17. Cooper J.A. Actin dynamics: tropomyosin provides stability. Curr Biol 2002, 12:R523-R525.
18. Shapland C., Hsuan J.J., Totty N.F., Lawson D. Purification of transgelin: a transformation and shape changing sensitive actin-gelling protein. J Cell Biol 1993, 121:1065-1073.
19. Assinder S.J., Stanton J.-A.L., Prasad P.D. Transgelin: an actin-binding protein and tumour suppressor. Int J Biochem Cell Biol 2009, 41:482-486.
20. Edlund S., Landstrom M., Heldin C.H., Aspenstrom P. Transforming growth factor-beta-induced mobilization of actin cytoskeleton requires signalling by small GTPases Cdc42 and RhoA. Mol Biol Cell 2002, 13:902-914.
21. Bakin A.V., Safina A., Rinehart C., Daroqui C., Darbary H., Helfman D.M. A critical role of tropomyosin in TGF-β regulation of the actin cytoskeleton and cell motility in epithelial cells. Mol Biol Cell 2004, 107:4682-4694.
22. Untergasser G., Gander R., Lilg C., et al. Profiling molecular targets of TGF-β1 in prostate fibroblast-to-myofibroblast transdifferentiation. Mech Age Dev 2005, 126:59-69.
23. Prasad P.D., Stanton J.-A.L., Assinder S.J. Expression of the actin-associated protein transgelin (SM22) is decreased in prostate cancer. Cell Tiss Res 2010, 339:337-347.
24. Shapland C., Loings P., Lawson D. Identification of new actin-associated polypeptides that are modified by viral transformation and changes in cell shape. J Cell Biol 1988, 107:153-161.
25. Bakin A.V., Rinehart C., Tomlinson A.K., Arteaga C.L. P38 mitogen-activated protein kinase is required for TGF-β mediated fibroblastic transdifferentiation and cell migration. J Cell Science 2002, 115:3193-3206.
26. Shields J.M., Rogers-Graham K., Der C.J. Loss of transgelin in breast and colon tumors and in RIE-1 cells by ras deregulation of gene expression through raf independent pathways. J Biol Chem 2002, 277:9790-9799.
27. Seoane J., Pouponnot C., Stalker P., et al. TGF-β influences Myc, miz-1 and Smad to control the CDK inhibitor p15INK4b. Nat Cell Biol 2001, 3:400-408.
28. Pawlak G., Helfman D.M. Cytoskeletal changes in cell transformation and tumorigenesis. Curr Opin Gen Dev 2001, 11:41-47.
29. Button E., Shapland C., Lawson D. Actin, its associated proteins and metastasis. Cell Motil Cytoskel 1995, 30:247-251.
30. Franzen B., Linder S., Uryu K., et al. Expression of tropomyosin isoforms in benign and malignant human breast lesions. Br J Cancer 1996, 73:909-913.
31. Raval G.N., Bharadwaj S., Levine S., et al. Loss of expression of tropomyosin-1, a novel class II tumor suppressor that induces anoikis, in primary breast tumors. Oncogne 2003, 22:6194-6203.
32. Mukhopadhyay N.K., Cinar B., Mukhopadhyay L., et al. The Zinc finger binding protein Ras-responsive element binding protein-1 is a coregulator of the androgen receptor: implications for the role of the Ras pathway in enhancing androgenic signalling in prostate cancer. Mol Endocrinol 2007, 21:2056-2070.
33. Assinder S.J., Dong Q., Kovacevic Z., Richardson D.R. PI3-K/Akt and PTEN pathways: established and proposed biochemical integration in prostate cancer. Biochem J 2009, 417:411-421.